期刊文献+

终末期肾病的医疗保险补偿政策研究 被引量:2

Policy Research on Medical Insurance Reimbursement of End Stage Renal Syndrome
下载PDF
导出
摘要 终末期肾病透析造成了一定的社会经济负担,根据研究结果提出按病种定额支付方式的措施,改变现有的医疗保险补偿模式,为推广社区腹膜透析治疗、促进早期透析治疗、提高患者生存质量而服务。通过模拟方法计算了病人、医院、医保单位及药厂各方的损益率。 The paper analyzes the social econmic burden of dialysis caused by end - stage renal syndrome. According to the research findings , the authors recommondate a messurement based on unit rate payment method so as to advocate the PD in community, promote dialysis in the early stage and improve the quality of life. A simulation of risk benefit analysis was calculated from the view of different stakeholders, such as patient, hospital, third party and pharmaceutical industry.
出处 《中国卫生经济》 北大核心 2001年第5期24-26,共3页 Chinese Health Economics
关键词 中国 医疗保险 终末期肾病 补偿政策 筹资定额付费 end - stage renal syndrome, reimbursement policy , financing unit rate
  • 相关文献

参考文献2

  • 1中华医学会上海肾脏病学会.上海市透析移植登记统计[M].,..
  • 2上海市人民政府.上海市城镇职工基本医疗保险办法[M].,2000..

同被引文献16

  • 1Parving HH,Lehnert H,Brochner MJ, et al..The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J ].N Engl J Med,2001,345:910.
  • 2Lewis EJ,Hunsicker LG,Clarke WR,et al .Renoprotective effect of the angiotensin - receptor antagonist irbesartan in patients with nephropathy due to type 2diabetes[ J ]. N Engl J Med , 2001,345:851.
  • 3World Health Organization. Life tables for 191 countries. World mortality in 2000 [EB/OL]..http:∥www3.who.int/whosis/life tables/lifetables.cfm? path=evidence, life tables&language = english. 2002.
  • 4Stehouwer CD, Gall MA, Twisk JW, et al.Increased urinary albumin excretion, endothelial dysfunction, and chronic low- grade inflammation in type 2 diabetes:progressive, interrelated, and independently associated with risk of death [J ]. Diabetes, 2002,51:1 157.
  • 5Rodby RA, Chiou CF, Borenstein J, et al..The costeffectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy[J].Clin Ther, 2003, 25:2 103.
  • 6Palmer AJ,Annemans L, Roze S, et al.An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy; costeffectiveness of Irbesartan in Diabetic Nephropathy Trial(IDNT) in the Belgian, and French settings[J ]..Nephrol Dial Transplant, 2003,18:2 059.
  • 7Adler AI, Stevens R J, Manley SE, et al..Development and progression of nephropathy in type 2 diabetes:the United Kingdom Prospective Diabetes Study(UKPDS 64) [J ]. Kidney Int, 2003,63:225.
  • 8Walters DP,Gatling W,Houston AC,et al .Mortality in diabetic subjects:an eleven- year follow- up of a community - based population[J ].Diabet Med, 1994,11:968.?A
  • 9Eastman RC, Javitt JC, Herman WH, et al.Model of complications of NIDDM.I.Model construction and assumptions[J ]..Diabetes Care, 1997a,20(5):725.
  • 10Eastman RC, Javitt JC, Herman WH, et al.Model of complications of NIDDM.Ⅱ.Analysis of the health benefits and cost - effectiveness of treating NIDDM with the goal of normoglycemia[J].. Diabetes Care,1997b, 20(5):735.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部